Drug intelligence / Profile preview

simvastatin + amlodipine besylate

Development stage: Unknown
Lead developer: Merck Research Laboratories
Modality: Small Molecules
Administration: Oral

Overview

A combination of simvastatin, an HMG-CoA reductase inhibitor (statin) used to lower cholesterol levels, and amlodipine besylate, a calcium channel blocker used for hypertension and angina. This combination requires careful dosing consideration due to a clinically significant drug interaction. Amlodipine inhibits the CYP3A4-mediated metabolism of simvastatin, leading to increased simvastatin plasma concentrations and potentially higher risk of adverse effects such as myopathy and rhabdomyolysis.

Other names: Amlodipine and simvastatin

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CYP3A4 (Cytochrome P450 3A4)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on simvastatin + amlodipine besylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simvastatin + amlodipine besylate.

Explore the full profile